Enable JavaScript to visit this website.

Resources

Title: 
Resources
Body: 

If you’d like more information about XALKORI® (crizotinib), non-small cell lung cancer (NSCLC), biomarker-driven therapy, or the ALK and ROS1 genes, you may want to start with the following downloads and links.

Title: 
Printable Resources
Body: 

Download and print these useful documents. They’ll help educate you about NSCLC, ALK and ROS1 testing, as well as XALKORI. They’ll also prepare you for what to expect while taking XALKORI.

Brochure

This brochure will provide information about XALKORI as a treatment for ALK-positive (ALK+) or ROS1-positve (ROS1+) metastatic NSCLC to help you get the most out of your treatment and understand what to expect.

Download
XALKORI® (crizotinib) patient brochure
Discussion Guide

This guide is meant to educate you on the roles and responsibilities of the members of your care team, with an emphasis on how to talk to your doctors, nurses, and loved ones.

Download
Discussion guide
Biomarker Testing Guide & Glossary

This guide and glossary is meant to educate you about biomarker testing and medical language associated with understanding XALKORI and ALK-positive (ALK+) or ROS1-positive (ROS1+) metastatic NSCLC.

Download
Biomarker testing guide and glossary
Financial Assistance Brochure

This brochure explains how to get XALKORI and details the financial assistance programs from Pfizer that may help you pay for your medicine.

Download
XALKORI® (crizotinib) financial assistance brochure
Title: 
Useful links
Body: 

Additional education and support for your treatment journey

If you’d like to explore other resources to learn more about cancer care and how it’s changing, consider the following:

It's also a good idea to check with your hospital or cancer care team for information about support groups near you.

Third-party websites being linked to are neither owned or controlled by Pfizer.
Pfizer does not endorse and is not responsible for the content or services of these sites.

Resources
If you’d like more information about XALKORI® (crizotinib) non-small cell lung cancer (NSCLC) biomarker-driven therapy, or the ALK and ROS1 genes, you may want to start with the following downloads and links.